JP2024536039A - GABAA α5受容体モジュレーターとしての二環式アミン誘導体 - Google Patents

GABAA α5受容体モジュレーターとしての二環式アミン誘導体 Download PDF

Info

Publication number
JP2024536039A
JP2024536039A JP2024518133A JP2024518133A JP2024536039A JP 2024536039 A JP2024536039 A JP 2024536039A JP 2024518133 A JP2024518133 A JP 2024518133A JP 2024518133 A JP2024518133 A JP 2024518133A JP 2024536039 A JP2024536039 A JP 2024536039A
Authority
JP
Japan
Prior art keywords
methyl
methoxy
tetrahydro
naphthyridine
triazol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024518133A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024536039A5 (cg-RX-API-DMAC7.html
Inventor
ザボー、ジェルジュ
ポトル、アッティラ
エルデーイ、ペーテル
バタ、イムレ
ジェルジュ、イシュトバーン トゥーローシュ
ラースロー カプシュ、ガーボル
エーリアーシュ、オリヴィエ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Richter Gedeon Nyrt
Original Assignee
Richter Gedeon Nyrt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Richter Gedeon Nyrt filed Critical Richter Gedeon Nyrt
Publication of JP2024536039A publication Critical patent/JP2024536039A/ja
Publication of JP2024536039A5 publication Critical patent/JP2024536039A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
JP2024518133A 2021-09-29 2022-09-28 GABAA α5受容体モジュレーターとしての二環式アミン誘導体 Pending JP2024536039A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
HUP2100338A HU231691B1 (hu) 2021-09-29 2021-09-29 GABAA ALFA5 receptor modulátor hatású biciklusos aminszármazékok
HUP2100338 2021-09-29
PCT/IB2022/059214 WO2023053015A1 (en) 2021-09-29 2022-09-28 BICYCLIC AMINE DERIVATIVES AS GABAA α5 RECEPTOR MODULATORS

Publications (2)

Publication Number Publication Date
JP2024536039A true JP2024536039A (ja) 2024-10-04
JP2024536039A5 JP2024536039A5 (cg-RX-API-DMAC7.html) 2025-10-01

Family

ID=89993434

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024518133A Pending JP2024536039A (ja) 2021-09-29 2022-09-28 GABAA α5受容体モジュレーターとしての二環式アミン誘導体

Country Status (20)

Country Link
US (1) US20250051323A1 (cg-RX-API-DMAC7.html)
EP (1) EP4408842A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024536039A (cg-RX-API-DMAC7.html)
KR (1) KR20240089056A (cg-RX-API-DMAC7.html)
CN (1) CN118284606A (cg-RX-API-DMAC7.html)
AR (1) AR127182A1 (cg-RX-API-DMAC7.html)
CA (1) CA3231776A1 (cg-RX-API-DMAC7.html)
CL (1) CL2024000893A1 (cg-RX-API-DMAC7.html)
CO (1) CO2024005424A2 (cg-RX-API-DMAC7.html)
CU (1) CU20240013A7 (cg-RX-API-DMAC7.html)
EC (1) ECSP24032316A (cg-RX-API-DMAC7.html)
GE (2) GEAP202416510A (cg-RX-API-DMAC7.html)
HU (1) HU231691B1 (cg-RX-API-DMAC7.html)
IL (1) IL311640A (cg-RX-API-DMAC7.html)
JO (1) JOP20240057A1 (cg-RX-API-DMAC7.html)
MX (1) MX2024003812A (cg-RX-API-DMAC7.html)
PE (1) PE20240816A1 (cg-RX-API-DMAC7.html)
TW (1) TW202330518A (cg-RX-API-DMAC7.html)
WO (1) WO2023053015A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202403230B (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024251133A1 (zh) * 2023-06-05 2024-12-12 武汉人福创新药物研发中心有限公司 作为α5-GABAA受体调节剂的杂环化合物及其用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013543852A (ja) * 2010-11-09 2013-12-09 エフ.ホフマン−ラ ロシュ アーゲー トリアゾール誘導体及びその神経障害に対する使用
WO2020065597A1 (en) * 2018-09-28 2020-04-02 Richter Gedeon Nyrt. Bicyclic derivatives as gabaa α5 receptor modulators
JP2020510621A (ja) * 2016-12-08 2020-04-09 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft Gaba a alpha5 pamとしての新規イソキサゾリルエーテル誘導体

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU230518B1 (hu) 2005-12-20 2016-10-28 Richter Gedeon Nyrt. Bradykinin B1 receptor szelektív antagonista hatással rendelkező új fenatridin származékok, eljárás előállításukra, és az ezeket tartalmazó gyógyszerkészítmények
HUP0600809A3 (en) 2006-10-27 2008-09-29 Richter Gedeon Nyrt New phenylsulfamoyl-benzamide derivatives as bradykinin antagonists, process and intermediates for their preparation and pharmaceutical compositions containing them
HUP0600810A3 (en) 2006-10-27 2008-09-29 Richter Gedeon Nyrt New sulfonamide derivatives as bradykinin antagonists, process and intermediates for their preparation and pharmaceutical compositions containing them
HUP0600808A3 (en) 2006-10-27 2008-09-29 Richter Gedeon Nyrt New benzamide derivatives as bradykinin antagonists, process for their preparation and pharmaceutical compositions containing them
US7943619B2 (en) 2007-12-04 2011-05-17 Hoffmann-La Roche Inc. Isoxazolo-pyridazine derivatives
WO2014001278A1 (en) 2012-06-26 2014-01-03 Aniona Aps A phenyl triazole derivative and its use for modulating the gabaa receptor complex
EP2885290B1 (en) 2012-06-26 2017-10-18 Saniona A/S A phenyl triazole derivative and its use for modulating the gabaa receptor complex
WO2014001279A1 (en) 2012-06-26 2014-01-03 Aniona Aps A phenyl triazole derivative and its use for modulating the gabaa receptor complex
HUP1300139A2 (en) 2013-03-06 2014-09-29 Richter Gedeon Nyrt Phenoxypiperidine h3 antagonists
EP4032889B1 (en) 2013-12-20 2026-05-06 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
EP4129297A1 (en) 2016-03-18 2023-02-08 UWM Research Foundation, Inc. Treatment of cognitive and mood symptoms in neurodegenerative and neuropsychiatric disorders with alpha5-containing gabaa receptor agonists
HU231057B1 (hu) 2017-03-13 2020-04-28 Richter Gedeon Nyrt Gyógyászatilag hatékony aril-szubsztituált pirazolo[1,5-a]pirimidin származékok
HU231058B1 (hu) 2017-03-13 2020-04-28 Richter Gedeon Nyrt. Gyógyászatilag hatékony aliciklusos-szubsztituált pirazolo[1,5-a]pirimidin származékok
TW201938171A (zh) 2017-12-15 2019-10-01 匈牙利商羅特格登公司 作為血管升壓素V1a受體拮抗劑之三環化合物
HU231206B1 (hu) 2017-12-15 2021-10-28 Richter Gedeon Nyrt. Triazolobenzazepinek
AU2019286312B2 (en) 2018-06-13 2023-08-17 F. Hoffmann-La Roche Ag New isoxazolyl ether derivatives as GABA A alpha5 PAM
HU231333B1 (hu) 2018-07-13 2023-01-28 Richter Gedeon Nyrt Spirokromán származékok
HU231478B1 (hu) 2018-07-13 2024-02-28 Richter Gedeon Nyrt. Szubsztituált (aza)indol származékok
HU231414B1 (hu) 2018-07-13 2023-08-28 Richter Gedeon Nyrt. Tiadiazin származékok
BR102019014802A2 (pt) 2018-07-20 2020-02-04 Boehringer Ingelheim Int difluorometil-fenil triazóis
TWI901650B (zh) * 2020-03-26 2025-10-21 匈牙利商羅特格登公司 啶及吡啶并〔3,4-c〕嗒衍生物

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013543852A (ja) * 2010-11-09 2013-12-09 エフ.ホフマン−ラ ロシュ アーゲー トリアゾール誘導体及びその神経障害に対する使用
JP2020510621A (ja) * 2016-12-08 2020-04-09 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft Gaba a alpha5 pamとしての新規イソキサゾリルエーテル誘導体
WO2020065597A1 (en) * 2018-09-28 2020-04-02 Richter Gedeon Nyrt. Bicyclic derivatives as gabaa α5 receptor modulators

Also Published As

Publication number Publication date
HUP2100338A1 (hu) 2023-04-28
PE20240816A1 (es) 2024-04-18
AR127182A1 (es) 2023-12-27
AU2022357572B2 (en) 2026-08-06
GEP20257812B (en) 2025-10-27
CO2024005424A2 (es) 2024-05-10
MX2024003812A (es) 2024-04-25
GEAP202416510A (en) 2024-08-12
US20250051323A1 (en) 2025-02-13
CN118284606A (zh) 2024-07-02
TW202330518A (zh) 2023-08-01
WO2023053015A1 (en) 2023-04-06
ECSP24032316A (es) 2024-05-31
EP4408842A1 (en) 2024-08-07
ZA202403230B (en) 2024-12-18
CA3231776A1 (en) 2023-04-06
HU231691B1 (hu) 2025-10-28
KR20240089056A (ko) 2024-06-20
AU2022357572A1 (en) 2024-05-02
CL2024000893A1 (es) 2024-09-06
CU20240013A7 (es) 2024-11-15
IL311640A (en) 2024-05-01
JOP20240057A1 (ar) 2024-03-20

Similar Documents

Publication Publication Date Title
EP4126858B1 (en) Dihydro-2-pyrrolo[3,4-c]pyridine derivatives as gabaa a5 receptor modulators
EP3856342B1 (en) Bicyclic derivatives as gabaa a5 receptor modulators
JP7805946B2 (ja) GABA Aアルファ5受容体調節剤としてのナフチリジンおよびピリド[3,4-c]ピリダジン誘導体
EA006234B1 (ru) Производные имидазопиримидина в качестве лигандов для гамк рецепторов
US20250051323A1 (en) BICYCLIC AMINE DERIVATIVES AS GABAA alpha5 RECEPTOR MODULATORS
EA052124B1 (ru) БИЦИКЛИЧЕСКИЕ АМИНОПРОИЗВОДНЫЕ В КАЧЕСТВЕ МОДУЛЯТОРОВ α5 РЕЦЕПТОРОВ GABAA
EA049237B1 (ru) ПРОИЗВОДНЫЕ НАФТИРИДИНА И ПИРИДО[3,4-c]ПИРИДАЗИНА В КАЧЕСТВЕ МОДУЛЯТОРОВ АЛЬФА 5 РЕЦЕПТОРОВ GABAA
EA045543B1 (ru) БИЦИКЛИЧЕСКИЕ ПРОИЗВОДНЫЕ КАК МОДУЛЯТОРЫ α5 РЕЦЕПТОРОВ GABAA
EA049500B1 (ru) ПРОИЗВОДНЫЕ 1,3-ДИГИДРО-2Н-ПИРРОЛО[3,4-с]ПИРИДИНА КАК МОДУЛЯТОРЫ α5 РЕЦЕПТОРОВ GABAA
OA18535A (en) Heteroramatic Compounds and their use as Dopamine D1 Ligands.
HK1201527A1 (en) New indolizine derivatives, method for preparing same and pharmaceutical compositions containing them for the treatment of cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250922

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250922

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260622

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260623